Table 3.

Treatment-related adverse events that occurred in ≥20% of participants in the safety population.

	All patients (n = 30)		200 mg cohort (n = 15)		300 mg cohort (n = 15)
	All grades	Grade 3–4	All grades	Grade 3–4	All grades	Grade 3–4
Any events	29 (97%)	22 (73%)	14 (93%)	9 (60%)	15 (100%)	13 (87%)
Rash	25 (83%)	15 (50%)	11 (73%)	6 (40%)	14 (93%)	9 (60%)
Diarrhea	21 (70%)	4 (13%)	9 (60%)	1 (7%)	12 (80%)	3 (20%)
Increased alanine aminotransferas	20 (67%)	2 (7%)	9 (60%)	1 (7%)	11 (73%)	1 (7%)
Increased aspartate aminotransferase	19 (63%)	1 (3%)	10 (67%)	1 (7%)	9 (60%)	0
Itch	18 (60%)	0	8 (53%)	0	10 (67%)	0
Increased conjugated bilirubin	16 (53%)	0	7 (47%)	0	9 (60%)	0
Xerosis cutis	16 (53%)	0	8 (53%)	0	8 (53%)	0
Paronychia	15 (50%)	1 (3%)	5 (33%)	0	10 (67%)	1 (7%)
Increased γ-glutamyltransferase	11 (37%)	3 (10%)	6 (40%)	2 (13%)	5 (33%)	1 (7%)
Mouth ulcer	10 (33%)	2 (7%)	2 (13%)	0	8 (53%)	2 (13%)
Increased blood bilirubin	10 (33%)	0	4 (27%)	0	6 (40%)	0
Cutaneous fissure	9 (30%)	1 (3%)	2 (13%)	0	7 (47%)	1 (7%)
Anorexia	9 (30%)	0	3 (20%)	0	6 (40%)	0
Eyelash growth	8 (27%)	0	4 (27%)	0	4 (27%)	0
Increased alkaline phosphatase	8 (27%)	0	6 (40%)	0	2 (13%)	0
Increased serum creatinine	7 (23%)	0	5 (33%)	0	2 (13%)	0
Nausea	6 (20%)	1 (3%)	1 (7%)	0	5 (33%)	1 (7%)
Skin exfoliation	6 (20%)	0	3 (20%)	0	3 (20%)	0
Extended QT interval of electrocardiogram	5 (17%)	0	4 (27%)	0	1 (7%)	0
Abdominal discomfort	4 (13%)	0	1 (7%)	0	3 (20%)	0
Conjunctivitis	4 (13%)	0	0	0	4 (27%)	0
Oral mucositis	4 (13%)	0	3 (20%)	0	1 (7%)	0
Alopecia	4 (13%)	0	1 (7%)	0	3 (20%)	0

Data are n (%). Treatment-related adverse events were assessed by investigators.

QT = time interval between the start of the Q wave and end of the T wave in the electrical cycle of the heart.